Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical outcomes of a new trifocal intraocular lens: RevIOL Tri-ED

Poster Details

First Author: B.Torun Acar TURKEY

Co Author(s):    E. Duman   S. Simsek                 

Abstract Details

Purpose:

To evaluate distance, intermediate and near visual acuity (VA), contrast sensitivity, defocus curve and patients’ satisfaction with a new trifocal intraocular lens (IOL) implantation after phacoemulsification.

Setting:

Haydarpasa Numune Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey

Methods:

Fifty-six eyes of 28 patients underwent uncomplicated phacoemulsification and trifocal IOL (Acriva Reviol Tri-ED) implantation. Postoperatively; distance (6 m), intermediate (66 cm) and near (33 cm) VA, refractive parameters, contrast sensitivity and defocus curve were measured. Additionally a questionnaire was used to subjectively evaluate the patients satisfaction.

Results:

Preoperative mean distance uncorrected visual acuity (UCVA) was 0.72±0.20 logMAR (range from 0.4 to 0.9). Six months after surgery binocular mean UCVA was -0.04±0.02, 0.19±0.12 and 0.08±0.11 for 6m, 66 cm and 33 cm, respectively. Mean preoperative spheric equivalent (SE) refraction was 0.70±2.28 D (range from -5.50D to 3.25D). Postoperatively, there was a statistically significant decrease in the SE value, reaching 0.24±0.42D (range from -0.75D to 0.75D) after one month. Six months postoperatively, the satisfaction was rated very good or good by 96.5%, 93% and 93% for far, intermediate and near vision.

Conclusions:

Bilateral Reviol tri-ED implantation provided good intermediate VA as well as distance and near VA. Patients were highly satisfied with their uncorrected vision after surgery.

Financial Disclosure:

NONE

Back to Poster listing